GT Biopharma, Inc. (GTBP) vs Skye Bioscience, Inc. (SKYE)
A side-by-side comparison of GT Biopharma, Inc. and Skye Bioscience, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
GTBP
GT Biopharma, Inc.
$6.37HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
SKYE
Skye Bioscience, Inc.
$1.62HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — GTBP vs SKYE
growth of $100 · dividends reinvested · last 10yGTBP -100.0% (-69.0%/yr)SKYE -99.8% (-47.3%/yr)SKYE compounded faster over this window
Log scale — wide-divergence pair
GTBP SKYE
GTBP vs SKYE: by the numbers
- •GTBP is the larger company ($8M vs $7M market cap).
Metrics side by side
Valuation
| Metric | GTBP | SKYE |
|---|---|---|
| P/B ratio | 2.25 | N/A |
Profitability
| Metric | GTBP | SKYE |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | 0.00% |
| ROE | -618.74% | N/A |
| ROIC | -457.75% | N/A |
Growth (annualized)
| Metric | GTBP | SKYE |
|---|---|---|
| Total return CAGR (5Y) | -73.13% | -60.42% |
Frequently asked
- How have GTBP and SKYE total returns compared?
- Over the past 10 years, GTBP delivered -68.76% and SKYE delivered -46.85% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.